AbCellera Biologics Inc.
ABCL evidence brief
What we can confirm
- BioSniper Score:
- 7.5 / 10
- Market Cap:
- $3.71B
- Lead Asset:
- ABCL575 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for ABCL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABCL
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines, with an internal pipeline that recently achieved its first clinical success with ABCL635 for menopausal vasomotor symptoms.
Key risk: Operating losses continue
BioSniper Score
Based on 4 of 6 signals
Market Cap
$3.71B
Cash Runway
—
Lead Asset
ABCL575 (Phase 1/Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for AbCellera Biologics Inc..
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines, with an internal pipeline that recently achieved its first clinical success with ABCL635 for menopausal vasomotor symptoms.
- AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for indications with high unmet medical need [sec_mda · as of 2026-08-05].
- As of 2026-06-30, the company reported cash & equivalents of $120.1M, total revenue of $4.0M, net income of -$55.4M, and shareholders' equity of $896.0M [sec].
- In 2025, AbCellera advanced its first two internal drug candidates into clinical development: ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis [sec · filed 2026-04-29].
- Positive top-line Phase 2 results for ABCL635 were reported in August 2026, showing clinically significant improvement in vasomotor symptoms from a single dose [news · published 2026-08-11].
- Total cash, cash equivalents, and marketable securities were $540.1M as of June 30, 2026 [sec_mda · as of 2026-08-05].
What works
- AbCellera has successfully transitioned into a clinical-stage company with an internal pipeline, achieving its first clinical success with ABCL635, which showed positive Phase 2 results [news · published 2026-08-11].
- The company maintains a strong liquidity position with total cash, cash equivalents, and marketable securities of $540.1M as of June 30, 2026 [sec_mda · as of 2026-08-05].
- AbCellera has secured significant government co-investments in the form of non-dilutive capital to help fund research and development and facility construction [sec_mda · as of 2026-02-24].
What to weigh
- The company reported a net loss of -$55.4M for the period ending June 30, 2026, with total revenue of only $4.0M, indicating ongoing operating losses [sec].
- AbCellera expects to continue to incur significant expenses for the foreseeable future as it invests in R&D, advances internal programs, and improves operations [sec_mda · as of 2026-08-05].
- The company's financial performance is heavily dependent on the success of its internal pipeline, which is still in early clinical stages and carries inherent development risks [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
AbCellera is a clinical-stage biotechnology company focused on antibody-based medicines.
“AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for indications with high unmet medical need.”
SEC MD&A · August 5, 2026
Positive Phase 2 results for ABCL635 were reported in August 2026.
“AbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms.”
News · August 11, 2026
AbCellera advanced ABCL635 and ABCL575 into clinical development in 2025.
“we successfully advanced our first two internal drug candidates into clinical development: ABCL635, a potential first-in-class non-hormonal treatment for vasomotor symptoms ("VMS"), and ABCL575”
SEC filings · April 29, 2026
Catalyst timeline
- 2025-03-13 · Phase1_Start: Phase Ib/IIa study of HCB101 in combination with multiple agents — Open-label, multicenter study evaluating safety and antitumor activity in advanced solid tumors.
- 2025-05-14 · AdCom: ABCL635 — Advisory committee review for ABCL635.
- 2025-05-30 · AdCom: ABCL575 — Advisory committee review for ABCL575.
- 2025-06-23 · Phase2_Start: Phase 1/2 study of ABCL635 in healthy participants and postmenopausal women — First-in-human study evaluating ABCL635 for vasomotor symptoms.
- 2025-07-25 · Phase1_Start: Phase 1 single-ascending dose study of ABCL575 in healthy participants — First-in-human study for ABCL575.
Risks & what to watch (3)›
Key risks
- Operating losses continue — Net loss of -$55.4M on revenue of $4.0M as of 2026-06-30 [sec].
- Pipeline stage risk — Internal pipeline is early-stage; only two candidates in clinical development as of 2025 [sec · filed 2026-04-29].
- Expense growth expected — Company expects to continue incurring significant expenses for R&D and operations [sec_mda · as of 2026-08-05].
What to watch
- Top-line Phase 2 data for ABCL635 anticipated in Q3 2026 [sec_mda · as of 2026-05-11].
- Enrollment and progress of the Phase 2 study for ABCL635, which is currently enrolling [sec_mda · as of 2026-05-11].
- Advancement of ABCL575 into clinical development and any interim data readouts [sec · filed 2026-04-29].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run AbCellera Biologics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AbCellera Biologics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.46 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
137
Total value held
$429.1M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 30,275,938 | $105.7M |
| capital world investors | 13,361,096 | $46.6M |
| two sigma investments, lp | 10,562,065 | $36.9M |
| td waterhouse canada inc. | 9,564,659 | $33.6M |
| ubs am, a distinct business unit of ubs asset management americas llc | 7,575,476 | $26.4M |
| ubs group ag | 4,209,052 | $14.7M |
| arrowmark colorado holdings llc | 4,105,095 | $14.3M |
| blackrock, inc. | 4,040,236 | $14.1M |
| driehaus capital management llc | 4,024,779 | $14.0M |
| goldman sachs group inc | 3,751,212 | $13.1M |
Showing top 10 of 137 institutional holders of AbCellera Biologics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 18.9%
- Days to cover
- 8.8
- Shares short
- 44,457,643
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABCL short interestGovernance
Frequently asked questions
What is the AI investment thesis for AbCellera Biologics Inc.?
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines, with an internal pipeline that recently achieved its first clinical success with ABCL635 for menopausal vasomotor symptoms.
What is AbCellera Biologics Inc.'s lead drug candidate?
AbCellera Biologics Inc.'s most advanced tracked candidate is ABCL575 (Phase 1/Phase 2) for Healthy Volunteers.
Who is the CEO of AbCellera Biologics Inc.?
Dr. Carl L.G. Hansen Ph.D. is the chief executive officer of AbCellera Biologics Inc. (ABCL).
Where is AbCellera Biologics Inc. headquartered?
AbCellera Biologics Inc. (ABCL) is headquartered in Vancouver, BC, Canada.
What therapeutic areas does AbCellera Biologics Inc. focus on?
AbCellera Biologics Inc. develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.